James Sabry at #JPM24 (Brian Benton Photography)
May 28, 2024 04:09 AM EDTUpdated 06:08 AM
People
Bioregnum

Af­ter 14 years call­ing part­ner­ing shots at Genen­tech/Roche, James Sabry is head­ed back in­to the biotech fray

James Sabry, the long­time doyen of biotech deal­mak­ers from his glob­al perch at Roche/Genen­tech, is jump­ing to the US biotech scene.

The Basel-based phar­ma gi­ant …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

In­side BAR­DA's multi­bil­lion-dol­lar ef­fort to fund long-shot biotechs for Covid

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

Im­munol­o­gy biotech Alu­mis se­cures $250M in shrunk­en IPO

A service from the Financial Times